Guggenheim Raises CG Oncology Target to $120
The sizable target increase supports a bullish view, while the signal reflects a single analyst opinion rather than a confirmed change in fundamentals.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The sizable target increase supports a bullish view, while the signal reflects a single analyst opinion rather than a confirmed change in fundamentals.
What happened, with direct paths to the underlying reporting
Guggenheim raised its CG Oncology price target to $120 from an $80 posted price, indicating substantial analyst-assessed upside.
Target: $120
Posted price: $80
Analyst firm: Guggenheim
Analyst: Brad Canino
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.